Zai Lab

Update in progress

ZLAB (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing, and commercializing medicines in oncology, immunology, neuroscience, and infectious diseases. Its products include Zejula (PARP inhibitor for ovarian cancer); VYVGART (IgG1 antibody fragment for generalized myasthenia gravis and CIDP); NUZYRA; Optune; Qinlock; Xacduro; and Augtyro. Based in Pudong, China, founded in 2013, it collaborates with Tesaro, NovoCure, Deciphera, Paratek, argenx, Turning Point, Entasis, Karuna, and Pfizer.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.67; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.24; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.25; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.38; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive